Cargando…
Cardiac resynchronization therapy and its effects in patients with type 2 DIAbetes mellitus OPTimized in automatic vs. echo guided approach. Data from the DIA-OPTA investigators
OBJECTIVES: To evaluate the effects of cardiac resynchronization therapy (CRTd) in patients with type 2 diabetes mellitus (T2DM) optimized via automatic vs. echocardiography-guided approach. BACKGROUND: The suboptimal atrio-ventricular (AV) and inter-ventricular (VV) delays optimization reduces CRTd...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7700711/ https://www.ncbi.nlm.nih.gov/pubmed/33248462 http://dx.doi.org/10.1186/s12933-020-01180-8 |
_version_ | 1783616343828856832 |
---|---|
author | Sardu, Celestino Paolisso, Pasquale Ducceschi, Valentino Santamaria, Matteo Sacra, Cosimo Massetti, Massimo Ruocco, Antonio Marfella, Raffaele |
author_facet | Sardu, Celestino Paolisso, Pasquale Ducceschi, Valentino Santamaria, Matteo Sacra, Cosimo Massetti, Massimo Ruocco, Antonio Marfella, Raffaele |
author_sort | Sardu, Celestino |
collection | PubMed |
description | OBJECTIVES: To evaluate the effects of cardiac resynchronization therapy (CRTd) in patients with type 2 diabetes mellitus (T2DM) optimized via automatic vs. echocardiography-guided approach. BACKGROUND: The suboptimal atrio-ventricular (AV) and inter-ventricular (VV) delays optimization reduces CRTd response. Therefore, we hypothesized that automatic CRTd optimization might improve clinical outcomes in T2DM patients. METHODS: We designed a prospective, multicenter study to recruit, from October 2016 to June 2019, 191 consecutive failing heart patients with T2DM, and candidate to receive a CRTd. Study outcomes were CRTd responders rate, hospitalizations for heart failure (HF) worsening, cardiac deaths and all cause of deaths in T2DM patients treated with CRTd and randomly optimized via automatic (n 93) vs. echocardiography-guided (n 98) approach at 12 months of follow-up. RESULTS: We had a significant difference in the rate of CRTd responders (68 (73.1%) vs. 58 (59.2%), p 0.038), and hospitalizations for HF worsening (12 (16.1%) vs. 22 (22.4%), p 0.030) in automatic vs. echocardiography-guided group of patients. At multivariate Cox regression analysis, the automatic guided approach (3.636 [1.271–10.399], CI 95%, p 0.016) and baseline highest values of atrium pressure (automatic SonR values, 2.863 [1.537–6.231], CI 95%, p 0.006) predicted rate of CRTd responders. In automatic group, we had significant difference in SonR values comparing the rate of CRTd responders vs. non responders (1.24 ± 0.72 g vs. 0.58 ± 0.46 g (follow-up), p 0.001), the rate of hospitalizations for HF worsening events (0.48 ± 0.29 g vs. 1.18 ± 0.43 g, p 0.001), and the rate of cardiac deaths ( 1.13 ± 0.72 g vs. 0.65 ± 0.69 g, p 0.047). CONCLUSIONS: Automatic optimization increased CRTd responders rate, and reduced hospitalizations for HF worsening. Intriguingly, automatic CRTd and highest baseline values of SonR could be predictive of CRTd responders. Notably, there was a significant difference in SonR values for CRTd responders vs. non responders, and about hospitalizations for HF worsening and cardiac deaths. Clinical trial ClinicalTrials.gov Identifier NCT04547244. |
format | Online Article Text |
id | pubmed-7700711 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-77007112020-11-30 Cardiac resynchronization therapy and its effects in patients with type 2 DIAbetes mellitus OPTimized in automatic vs. echo guided approach. Data from the DIA-OPTA investigators Sardu, Celestino Paolisso, Pasquale Ducceschi, Valentino Santamaria, Matteo Sacra, Cosimo Massetti, Massimo Ruocco, Antonio Marfella, Raffaele Cardiovasc Diabetol Original Investigation OBJECTIVES: To evaluate the effects of cardiac resynchronization therapy (CRTd) in patients with type 2 diabetes mellitus (T2DM) optimized via automatic vs. echocardiography-guided approach. BACKGROUND: The suboptimal atrio-ventricular (AV) and inter-ventricular (VV) delays optimization reduces CRTd response. Therefore, we hypothesized that automatic CRTd optimization might improve clinical outcomes in T2DM patients. METHODS: We designed a prospective, multicenter study to recruit, from October 2016 to June 2019, 191 consecutive failing heart patients with T2DM, and candidate to receive a CRTd. Study outcomes were CRTd responders rate, hospitalizations for heart failure (HF) worsening, cardiac deaths and all cause of deaths in T2DM patients treated with CRTd and randomly optimized via automatic (n 93) vs. echocardiography-guided (n 98) approach at 12 months of follow-up. RESULTS: We had a significant difference in the rate of CRTd responders (68 (73.1%) vs. 58 (59.2%), p 0.038), and hospitalizations for HF worsening (12 (16.1%) vs. 22 (22.4%), p 0.030) in automatic vs. echocardiography-guided group of patients. At multivariate Cox regression analysis, the automatic guided approach (3.636 [1.271–10.399], CI 95%, p 0.016) and baseline highest values of atrium pressure (automatic SonR values, 2.863 [1.537–6.231], CI 95%, p 0.006) predicted rate of CRTd responders. In automatic group, we had significant difference in SonR values comparing the rate of CRTd responders vs. non responders (1.24 ± 0.72 g vs. 0.58 ± 0.46 g (follow-up), p 0.001), the rate of hospitalizations for HF worsening events (0.48 ± 0.29 g vs. 1.18 ± 0.43 g, p 0.001), and the rate of cardiac deaths ( 1.13 ± 0.72 g vs. 0.65 ± 0.69 g, p 0.047). CONCLUSIONS: Automatic optimization increased CRTd responders rate, and reduced hospitalizations for HF worsening. Intriguingly, automatic CRTd and highest baseline values of SonR could be predictive of CRTd responders. Notably, there was a significant difference in SonR values for CRTd responders vs. non responders, and about hospitalizations for HF worsening and cardiac deaths. Clinical trial ClinicalTrials.gov Identifier NCT04547244. BioMed Central 2020-11-28 /pmc/articles/PMC7700711/ /pubmed/33248462 http://dx.doi.org/10.1186/s12933-020-01180-8 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Original Investigation Sardu, Celestino Paolisso, Pasquale Ducceschi, Valentino Santamaria, Matteo Sacra, Cosimo Massetti, Massimo Ruocco, Antonio Marfella, Raffaele Cardiac resynchronization therapy and its effects in patients with type 2 DIAbetes mellitus OPTimized in automatic vs. echo guided approach. Data from the DIA-OPTA investigators |
title | Cardiac resynchronization therapy and its effects in patients with type 2 DIAbetes mellitus OPTimized in automatic vs. echo guided approach. Data from the DIA-OPTA investigators |
title_full | Cardiac resynchronization therapy and its effects in patients with type 2 DIAbetes mellitus OPTimized in automatic vs. echo guided approach. Data from the DIA-OPTA investigators |
title_fullStr | Cardiac resynchronization therapy and its effects in patients with type 2 DIAbetes mellitus OPTimized in automatic vs. echo guided approach. Data from the DIA-OPTA investigators |
title_full_unstemmed | Cardiac resynchronization therapy and its effects in patients with type 2 DIAbetes mellitus OPTimized in automatic vs. echo guided approach. Data from the DIA-OPTA investigators |
title_short | Cardiac resynchronization therapy and its effects in patients with type 2 DIAbetes mellitus OPTimized in automatic vs. echo guided approach. Data from the DIA-OPTA investigators |
title_sort | cardiac resynchronization therapy and its effects in patients with type 2 diabetes mellitus optimized in automatic vs. echo guided approach. data from the dia-opta investigators |
topic | Original Investigation |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7700711/ https://www.ncbi.nlm.nih.gov/pubmed/33248462 http://dx.doi.org/10.1186/s12933-020-01180-8 |
work_keys_str_mv | AT sarducelestino cardiacresynchronizationtherapyanditseffectsinpatientswithtype2diabetesmellitusoptimizedinautomaticvsechoguidedapproachdatafromthediaoptainvestigators AT paolissopasquale cardiacresynchronizationtherapyanditseffectsinpatientswithtype2diabetesmellitusoptimizedinautomaticvsechoguidedapproachdatafromthediaoptainvestigators AT ducceschivalentino cardiacresynchronizationtherapyanditseffectsinpatientswithtype2diabetesmellitusoptimizedinautomaticvsechoguidedapproachdatafromthediaoptainvestigators AT santamariamatteo cardiacresynchronizationtherapyanditseffectsinpatientswithtype2diabetesmellitusoptimizedinautomaticvsechoguidedapproachdatafromthediaoptainvestigators AT sacracosimo cardiacresynchronizationtherapyanditseffectsinpatientswithtype2diabetesmellitusoptimizedinautomaticvsechoguidedapproachdatafromthediaoptainvestigators AT massettimassimo cardiacresynchronizationtherapyanditseffectsinpatientswithtype2diabetesmellitusoptimizedinautomaticvsechoguidedapproachdatafromthediaoptainvestigators AT ruoccoantonio cardiacresynchronizationtherapyanditseffectsinpatientswithtype2diabetesmellitusoptimizedinautomaticvsechoguidedapproachdatafromthediaoptainvestigators AT marfellaraffaele cardiacresynchronizationtherapyanditseffectsinpatientswithtype2diabetesmellitusoptimizedinautomaticvsechoguidedapproachdatafromthediaoptainvestigators |